Fairvalue-Calculator Fairvalue-Calculator
EN DE

Getinge AB (GNGBY) Fair Value & Analysis

Healthcare · US · Market cap $5.5B

Price$19.77
Fair Value$18.14
Upside-8.2%
Quality95/100
Evidence: High Range $10.62 – $19.33

Analysis

Getinge AB (GNGBY) currently trades at $19.77, while our model-based Fair Value estimate is $18.14 — implying the stock looks roughly 8.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solutions. In addition, the company provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, vascular and cardiothoracic surgery equipment, peripheral stenting, OEM solutions, and beating heart surgery equipment; and operating room equipment, anesthesia, advanced patient monitoring, and operating room integration solutions. Further, it offers pre-cleaning, cleaning and disinfection, sterilization, consumables, endoscope reprocessing, and sterile supply management solutions; connected medical devices, and patient flow management; and low temperature steril…

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.